BTL Industries v. Advanced Regenerative Medicine — Default Judgment & Injunction in 314 Days
BTL Industries secured a default judgment and permanent injunction against Advanced Regenerative Medicine USA and James Vaughn, barring use of BTL’s electromagnetic body-treatment trademarks including EMSHAPE and EMSLIM. Four patents covering magnetic stimulation therapy were at stake, and the case closed in under a year after defendants failed to mount a defence.
Default judgment secures BTL’s EM body-treatment IP in under a year
BTL Industries, Inc., a developer of electromagnetic aesthetic and therapeutic devices, filed suit on 29 March 2023 in the Delaware District Court against Advanced Regenerative Medicine LLC, Advanced Regenerative Medicine USA LLC (ARM USA), and individual defendant James Vaughn. BTL asserted infringement of four US patents covering aesthetic magnetic field treatments and magnetic stimulation methods, alongside trademark claims centred on brand identifiers associated with its muscle-stimulation product lines.
The case closed on 6 February 2024 via default judgment under Federal Rule of Civil Procedure 55(b) — a mechanism available when a defendant fails to appear or otherwise defend. Chief Judge William C. Bryson entered judgment in favour of BTL against ARM USA and James Vaughn, ordering a permanent injunction prohibiting further use of BTL’s registered trademarks and the confusingly similar designations EMSHAPE, EMSLIM, EMSTRENGTH, and HIPEM in marketing and advertising. The court retained jurisdiction to enforce the injunctive terms.
Resolution in 314 days is consistent with uncontested default proceedings, which typically close faster than litigated matters. The absence of defendant counsel on record and the default mechanism together suggest ARM USA and Vaughn did not meaningfully engage with the litigation. What remains unknown from the public record is whether any monetary damages were separately assessed, and the status of the original ARM LLC entity, which does not appear as a named party in the final judgment.
Filing to settlement in 314 days
314 days — faster than most contested patent infringement cases at District Court level
Default judgment and permanent injunction entered in favour of BTL Industries
Rule 55(b) default — what it means when defendants don’t respond
A Rule 55(b) default judgment is entered when a defendant fails to appear or respond to the complaint. The court does not reach the merits of patent or trademark validity — it accepts the plaintiff’s well-pleaded allegations as true. Here, ARM USA and Vaughn’s failure to defend meant BTL’s claims were treated as established, enabling the court to grant injunctive relief without a trial.
No merits ruling on patent validityFour marks enjoined — EMSHAPE, EMSLIM, EMSTRENGTH, HIPEM
The injunction bars defendants from using BTL’s registered trademarks and four specifically named confusingly similar marks in marketing and advertising. Defendants are also required to scrub all references from any website used to promote their products. The scope is product-marketing focused — the order does not appear to restrict the underlying technology use beyond the trademark context, though patent claims were also pleaded.
Marketing and web presence coveredFour EM stimulation patents asserted — validity untested
BTL asserted US10478634B2, US10695575B1, US9636519B2, and US11266852B2 — a portfolio spanning aesthetic magnetic field treatment methods and therapeutic magnetic stimulation devices. Because judgment was entered by default, none of these patents was subjected to validity or claim construction scrutiny. Competitors cannot treat this outcome as confirmation of patent validity; an IPR or inter partes challenge remains available.
Validity untested — IPR risk remainsIndividual defendant named — personal liability in IP enforcement
James Vaughn was named alongside the corporate entity ARM USA and is bound by the injunction personally. Naming individuals alongside companies in IP enforcement actions is a recognised strategy to prevent circumvention through corporate restructuring. The court’s retention of jurisdiction for ongoing enforcement reinforces BTL’s ability to pursue contempt proceedings if the injunction is violated.
Personal injunction — enforcement leverageFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | BTL Industries, Inc. | Company | Electromagnetic aesthetic device maker — holder of US10478634B2 and related EM stimulation patentsSearch in Eureka ↗ |
| Defendant | Advanced Regenerative Medicine, LLC | Company | Advanced Regenerative Medicine USA LLC and James Vaughn — aesthetic treatment providers accused of trademark and patent misuseSearch in Eureka ↗ |
| Plaintiff counsel | Alexis Stombaugh | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Chandrika Vira | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | John C. Rozendaal | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Josephine J. Kim | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Samantha G. Wilson | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The default judgment is limited in legal precedential weight — it does not constitute a merits finding on patent infringement or validity. The operative relief is the permanent injunction, which binds ARM USA and Vaughn across all marketing channels and web presence. The court’s retention of jurisdiction is significant: BTL can return for contempt proceedings without filing a new action, giving it durable enforcement leverage. The omission of the original ARM LLC entity from the final judgment is a gap worth noting for practitioners tracking related entities.
US10478634B2 — Aesthetic Electromagnetic Field Body Treatment
US10478634B2 (application US16/034793) is directed to aesthetic methods of treating biological structures using magnetic fields — the foundational technical claim covering non-invasive body-contouring and muscle-stimulation approaches. The portfolio also includes US10695575B1 and US11266852B2, covering magnetic stimulation methods and devices for therapeutic applications, and US9636519B2, covering earlier-generation electromagnetic treatment methods. Together, these patents span both the method of treatment and the device architecture, creating layered protection across the EM aesthetics workflow.
The electromagnetic body-treatment sector — anchored by devices branded under marks like EMSCULPT and equivalent designations — is commercially significant and growing. BTL’s four-patent portfolio, combined with registered trademark rights over treatment-associated brand names, positions it as a formidable enforcer in this space. For competitors developing EM-based muscle stimulation or aesthetic contouring devices, any product that uses pulsed electromagnetic fields to stimulate muscle contraction or treat subcutaneous tissue should be assessed against each of these four patent families. Claim scope has not been judicially construed in this case, so independent analysis is essential.
Should you run an FTO against BTL’s EM stimulation patent portfolio?
Any R&D team developing electromagnetic muscle-stimulation devices, aesthetic body-contouring systems, or pulsed magnetic field therapeutic equipment should treat BTL’s four-patent family as a primary FTO target. This case confirms BTL is willing to litigate — including against individual operators — and the trademark overlay means brand strategy must also be reviewed. Companies already marketing products under EM-adjacent names (including EMSHAPE-style designations) face both patent and trademark exposure.
PatSnap Eureka’s FTO Search Agent allows you to map your device’s method claims and hardware architecture against each of the four BTL patents in this case — US10478634B2, US10695575B1, US9636519B2, and US11266852B2. Set up claim monitoring alerts on these patent families to track any continuations, divisionals, or related applications that BTL may file. Early-stage FTO analysis is substantially cheaper than litigation defence, and this case underscores that BTL will not always face a contested defence.
Run a freedom-to-operate analysis on US10478634B2 to assess your product’s exposure
Run FTO in Eureka →Similar EM device patent litigation and aesthetic treatment IP cases
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the electromagnetic aesthetics IP landscape
BTL’s default win is an enforcement marker in a fast-growing, patent-dense market segment where brand and method protection overlap.
BTL’s portfolio breadth creates overlapping trademark and patent moats
Asserting four patents alongside trademark claims gives BTL layered protection — even if one patent is later invalidated, the trademark injunction survives independently. Companies commercialising EM body-treatment devices should audit both their product branding and their method claims against BTL’s registered marks and patent portfolio before market entry.
Default judgments don’t resolve patent validity — competitors should note this
The four BTL patents were never examined on the merits. Rivals considering an IPR petition against US10478634B2 or the related applications face no estoppel from this outcome. The default judgment strengthens BTL’s enforcement posture commercially but leaves the patents legally untested and potentially challengeable.
BTL v Advanced — key questions answered
BTL Industries obtained a default judgment and permanent injunction against Advanced Regenerative Medicine USA LLC and James Vaughn on 6 February 2024. The court, applying Rule 55(b), entered judgment in BTL’s favour after defendants failed to appear or defend. The injunction prohibits defendants from using BTL’s trademarks and the marks EMSHAPE, EMSLIM, EMSTRENGTH, and HIPEM.
BTL asserted four US patents: US10478634B2 (aesthetic method of biological structure treatment by magnetic field), US10695575B1 (magnetic stimulation methods and devices), US9636519B2, and US11266852B2. All four cover electromagnetic stimulation technology used in aesthetic and therapeutic body-treatment applications. Patent validity was not adjudicated due to the default judgment.
A Rule 55(b) default judgment does not constitute a merits finding on patent validity or infringement. The court accepts the plaintiff’s allegations as established due to the defendant’s failure to respond. BTL’s four patents were not subjected to claim construction or validity analysis, meaning competitors can still challenge them via inter partes review (IPR) at the USPTO without any estoppel from this outcome.
Naming an individual alongside corporate entities is a recognised IP enforcement strategy. It prevents circumvention of an injunction through corporate dissolution or restructuring, and it creates personal liability for ongoing infringement. The court’s injunction binds Vaughn individually, and the court retained jurisdiction to enforce those terms — enabling BTL to pursue contempt proceedings directly against him.
The injunction covers BTL’s registered trademarks (not individually named in the public verdict text) and four specifically identified confusingly similar marks: EMSHAPE, EMSLIM, EMSTRENGTH, and HIPEM. Defendants are barred from using these marks in marketing and advertising, and must remove all references from any website used to promote their products. The order is directed at promotional and digital channels.
PatSnap Eureka searches patents and litigation data to answer instantly.